Background: In Indonesia colorectal cancer ranks third. The incidence of colorectal cancer in Indonesia is 12.8 per 100,000 adult population. The main problem in the prevention of cancer is the amount of treatment costs and long therapy time. So choosing an effective therapy for colorectal cancer is needed. This relates to the costs incurred by the patient and the outcome obtained.
Objective: This study aims to determine the outcome of recurrence and survival of several colorectal cancer therapy regimens used in Prof. Dr. Margono Soekarjo and know about the cost effectiveness of colorectal cancer therapy regimens.
Methods: This research is an analytical observational study with retrospective data collection with cross sectional analitic research design.
Results: Of the 30 patients with colorectal cancer in this study, there were 5 therapeutic regimens. The therapeutic regimen with the lowest outcome of recurrence was 5FU + Capecitabine while the therapeutic regimen with a high survival rate was 5FU / LV. Patients who used the 5FU / LV, 5FU + Capecitabine and FOLFOX therapeutic regimens gave survival for 9.5 months, 8 months and 5.7 months respectively. Inceremental Cost Effectiveness Ratio (ICER) value with recurrence outcome for 5FU / LV regimen is Rp. 151,827.29 / month did not recur and for the Surgical + 5FU / LV or Capecitabine regimen was Rp. 7.216.48.00 Whereas in the ICER the outcome of survival is the ICER value for the 5FU / LV regimen of Rp. - 7,254,139.57 / month survival and for the 5FU + Capecitabine regimen Rp. - 260,312.55 / month survival.
Conclusion: The therapeutic regimen that has a low recurrence rate is 5FU + Capecitabine and a high survival rate is 5FU / LV. The therapeutic regimen for cost effectiveness based on the outcome of relapse is the 5FU + Capecitabine regimen. While the cost effectiveness therapy regimen based on survival outcomes is 5FU / LV.